Comparative Pharmacology
Head-to-head clinical analysis: CLARINEX D 12 HOUR versus DECABID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARINEX D 12 HOUR versus DECABID.
CLARINEX-D 12 HOUR vs DECABID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desloratadine is a long-acting tricyclic histamine antagonist selective for H1-receptor with additional anti-inflammatory properties. Pseudoephedrine is a sympathomimetic amine that acts as a vasoconstrictor via alpha-adrenergic receptors.
Decabid is a combination of chlorpheniramine (antihistamine) and pseudoephedrine (decongestant). Chlorpheniramine competitively antagonizes histamine at H1 receptors, reducing allergic symptoms. Pseudoephedrine acts as a sympathomimetic agent, stimulating alpha-adrenergic receptors to cause vasoconstriction, reducing nasal congestion.
1 tablet (5 mg desloratadine / 120 mg pseudoephedrine) orally every 12 hours.
1 capsule orally every 12 hours; each capsule contains 10 mg phenylephrine hydrochloride and 75 mg carbinoxamine maleate.
None Documented
None Documented
Desloratadine: 27 hours (terminal), allows once-daily dosing; pseudoephedrine: 4-6 hours (prolonged in alkaline urine).
12 hours (terminal); prolonged to 24 hours in renal impairment (CrCl <30 mL/min)
Desloratadine: 40.2% renal (unchanged and metabolites), 41.7% fecal; pseudoephedrine: 70-90% renal (unchanged).
Renal (50% as unchanged drug), fecal (40% as metabolites), biliary (10% as glucuronide conjugates)
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine/Decongestant Combination